Asymmetric dimethylarginine in patients with rheumatological diseases: a non-classical cardiovascular risk factor?

E. P. Kolesova; A. L. Maslyansky; O. P. Rotar; I. N. Grigorieva; I. N. Penin; А. O. Konradi

doi:10.18705/1607-419x-2019-25-5-510-519

Asymmetric dimethylarginine in patients with rheumatological diseases: a non-classical cardiovascular risk factor?

Arterial’naya Gipertenziya (Arterial Hypertension) ◽

10.18705/1607-419x-2019-25-5-510-519 ◽

2020 ◽

Vol 25 (5) ◽

pp. 510-519

Author(s):

E. P. Kolesova ◽

A. L. Maslyansky ◽

O. P. Rotar ◽

I. N. Grigorieva ◽

I. N. Penin ◽

...

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Cardiovascular Risk Factor ◽

Asymmetric Dimethylarginine ◽

Rheumatological Diseases

Get full-text (via PubEx)

Faculty Opinions recommendation of Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718059599.793481605 ◽

2013 ◽

Author(s):

Harald HHW Schmidt ◽

Robert Lukowski

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Cardiovascular Risk Factor ◽

Asymmetric Dimethylarginine ◽

Unexpected Effect

Get full-text (via PubEx)

Asymmetric Dimethylarginine: A Novel Cardiovascular Risk Factor in End-Stage Renal Disease

Journal of International Medical Research ◽

10.1177/147323001204000135 ◽

2012 ◽

Vol 40 (1) ◽

pp. 340-349 ◽

Cited By ~ 4

Author(s):

M Yusuf Alsagaff ◽

M Thaha ◽

M Aminuddin ◽

RM Yogiarto ◽

M Yogiantoro ◽

...

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Renal Disease ◽

Cardiovascular Risk Factor ◽

End Stage Renal Disease ◽

Asymmetric Dimethylarginine ◽

Stage Renal Disease ◽

End Stage

Get full-text (via PubEx)

The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor

Cardiovascular Research ◽

10.1016/s0008-6363(03)00500-5 ◽

2003 ◽

Vol 59 (4) ◽

pp. 824-833 ◽

Cited By ~ 251

Author(s):

R BOGER

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Cardiovascular Risk Factor ◽

Asymmetric Dimethylarginine

Get full-text (via PubEx)

Asymmetric Dimethylarginine: A Cardiovascular Risk Factor and a Uremic Toxin Coming of Age?

American Journal of Kidney Diseases ◽

10.1053/j.ajkd.2005.05.009 ◽

2005 ◽

Vol 46 (2) ◽

pp. 186-202 ◽

Cited By ~ 117

Author(s):

Jan T. Kielstein ◽

Carmine Zoccali

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Cardiovascular Risk Factor ◽

Asymmetric Dimethylarginine ◽

Coming Of Age ◽

Uremic Toxin

Get full-text (via PubEx)

Asymmetric Dimethylarginine, an Endogenous Inhibitor of Nitric Oxide Synthase, Explains the “L-Arginine Paradox” and Acts as a Novel Cardiovascular Risk Factor

Journal of Nutrition ◽

10.1093/jn/134.10.2842s ◽

2004 ◽

Vol 134 (10) ◽

pp. 2842S-2847S ◽

Cited By ~ 207

Author(s):

Rainer H. Böger

Keyword(s):

Nitric Oxide ◽

Risk Factor ◽

Cardiovascular Risk ◽

Nitric Oxide Synthase ◽

Cardiovascular Risk Factor ◽

Asymmetric Dimethylarginine ◽

Endogenous Inhibitor ◽

Oxide Synthase

Get full-text (via PubEx)

Letter by Chyrchel et al Regarding Article, “Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine”

Circulation ◽

10.1161/circulationaha.113.006284 ◽

2014 ◽

Vol 129 (13) ◽

Cited By ~ 1

Author(s):

Bernadeta Chyrchel ◽

Michał Chyrchel ◽

Andrzej Surdacki

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Cardiovascular Risk Factor ◽

Asymmetric Dimethylarginine ◽

Unexpected Effect

Get full-text (via PubEx)

Mo-W7:1 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, acts as a novel cardiovascular risk factor

Atherosclerosis Supplements ◽

10.1016/s1567-5688(06)80062-0 ◽

2006 ◽

Vol 7 (3) ◽

pp. 22-23

Author(s):

R.H. Böger

Keyword(s):

Nitric Oxide ◽

Risk Factor ◽

Cardiovascular Risk ◽

Nitric Oxide Synthase ◽

Cardiovascular Risk Factor ◽

Asymmetric Dimethylarginine ◽

Endogenous Inhibitor ◽

Oxide Synthase

Get full-text (via PubEx)

Effect of Hormone Replacement Therapy on Plasma Levels of the Cardiovascular Risk Factor Asymmetric Dimethylarginine: A Randomized, Placebo-Controlled 12-Week Study in Healthy Early Postmenopausal Women

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.2003-030584 ◽

2003 ◽

Vol 88 (9) ◽

pp. 4221-4226 ◽

Cited By ~ 45

Author(s):

Marinka S. Post ◽

Marieke O. Verhoeven ◽

Marius J. van der Mooren ◽

Peter Kenemans ◽

Coen D. A. Stehouwer ◽

...

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Hormone Replacement Therapy ◽

Replacement Therapy ◽

Postmenopausal Women ◽

Cardiovascular Risk Factor ◽

Plasma Levels ◽

Asymmetric Dimethylarginine ◽

Hormone Replacement ◽

Early Postmenopausal Women

Get full-text (via PubEx)

Response to Letters Regarding Article, “Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine”

Circulation ◽

10.1161/circulationaha.114.009343 ◽

2014 ◽

Vol 129 (13) ◽

Cited By ~ 5

Author(s):

Yohannes T. Ghebremariam ◽

Paea LePendu ◽

Jerry C. Lee ◽

Daniel A. Erlanson ◽

Anna Slaviero ◽

...

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Proton Pump Inhibitors ◽

Proton Pump ◽

Cardiovascular Risk Factor ◽

Asymmetric Dimethylarginine ◽

Unexpected Effect

Get full-text (via PubEx)

Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers

Pharmacological Research ◽

10.1016/j.phrs.2009.07.009 ◽

2009 ◽

Vol 60 (6) ◽

pp. 508-514 ◽

Cited By ~ 20

Author(s):

K. Kurz ◽

T. Teerlink ◽

M. Sarcletti ◽

G. Weiss ◽

R. Zangerle ◽

...

Keyword(s):

Risk Factor ◽

Cardiovascular Risk ◽

Cardiovascular Risk Factor ◽

Immune Activation ◽

Asymmetric Dimethylarginine ◽

Plasma Concentrations ◽

Activation Markers ◽

Hiv 1

Get full-text (via PubEx)